Mirae Asset Global Investments Co. Ltd. Acquires New Stake in Novo Nordisk A/S $NVO

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 263,943 shares of the company’s stock, valued at approximately $10,006,000.

A number of other institutional investors have also modified their holdings of NVO. Profund Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 12.0% in the third quarter. Profund Advisors LLC now owns 21,874 shares of the company’s stock valued at $829,000 after buying an additional 2,352 shares during the last quarter. Vise Technologies Inc. grew its holdings in shares of Novo Nordisk A/S by 26.9% during the third quarter. Vise Technologies Inc. now owns 70,350 shares of the company’s stock worth $2,667,000 after buying an additional 14,915 shares during the last quarter. Americana Partners LLC grew its holdings in shares of Novo Nordisk A/S by 2.5% during the third quarter. Americana Partners LLC now owns 99,180 shares of the company’s stock worth $3,760,000 after buying an additional 2,423 shares during the last quarter. Armstrong Fleming & Moore Inc increased its position in Novo Nordisk A/S by 30.9% in the 3rd quarter. Armstrong Fleming & Moore Inc now owns 6,774 shares of the company’s stock valued at $257,000 after acquiring an additional 1,601 shares during the period. Finally, Laurel Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $123,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Barclays reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Finally, Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $59.44.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

Novo Nordisk A/S Trading Up 5.0%

Shares of NVO opened at $42.21 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The firm’s 50-day moving average is $40.84 and its two-hundred day moving average is $44.07. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The firm has a market capitalization of $188.45 billion, a P/E ratio of 10.32, a PEG ratio of 1.36 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The company had revenue of $11.98 billion during the quarter. On average, research analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.